X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHI’s Protein Engineering Summit
WALTHAM, Mass., April 27, 2012 /PRNewswire/ — X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced it will present novel methods of selecting for antibodies against targets on the surface of live cells at CHI’s Protein Engineering Summit (PEGS) and the associated Biologics Partnering Forum being held April 28th through May 4th in Boston, Massachusetts.
Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY, will present a talk entitled, “Predicting Antibody Binding Properties by Interrogation of Fully Human Libraries with Deep Sequencing” on Saturday, April 28th at 4:15 PM.
Yan Chen, M.D./Ph.D., Senior VP of Research and Development at X-BODY, will present a talk entitled, “Generation and Optimization of Fully Human VH Domain Antibodies and IgG Using dsDNA Display with Deep Sequence Hit Analysis” on Tuesday, May 1st at 3:05 PM.
A poster entitled, “Selection of Fully Human Antibodies Targeting HER2 Expressed on Live Cells with dsDNA Display and Massively Parallel Deep Sequencing Analysis” will also be presented by X-BODY at the conference on April 30th-May 1st.
X-BODY recently expanded its internal capabilities by hiring an expert team in performing live cell screening, deep sequence bioinformatics, and engineering. X-BODY’s novel proprietary system allows for performing antibody selections on live cells while simultaneously analyzing the cell binding characteristics of thousands of antibody hits. X-BODY is now applying this live cell selection platform in four research alliances forged since January 2011 which are funded by X-BODY’s research partners: Alvos Therapeutics, BioMed Valley Discoveries (established by the Stowers Institute for Medical Research), Tanabe Research Laboratories U.S.A., Inc. (an independent subsidiary of Mitsubishi Tanabe Pharma Corporation) and an undisclosed mid-cap biotechnology company. X-BODY BioSciences has also applied live cell antibody selection technology to its internal programs in Oncology and Ophthalmology.
About X-BODY BioSciences, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. X-BODY’s platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY’s versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The modular leads generated by X-BODY’s platform can be incorporated into VH domain, scFv, IgG and bispecific antibody formats. X-BODY’s lead molecule, XB-2202, is a potent inhibitor of PDGF Receptor Beta and has potential applications in treating Age-Related Macular Degeneration (AMD) and solid tumors.
SOURCE X-BODY BioSciences